ALK and non-small cell lung carcinoma: Clinical trials of combination therapy with mainstream targeted agents on NSCLC, such as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) were also suspended due to the limited therapeutic effects of the drugs (Rotow and Bivona, 2017).